// App-Quantinova.ai

918 : Efficacy and Safety of Filgotinib in Patients with Inadequate Response to Methotrexate, with 4 or < 4 Poor Prognostic Factors: A Post Hoc Analysis of the FINCH 1 Study

Researchers

Presenter

  • BERNARD COMBE

Principal Investigators

  • Yoshiya Tanaka

  • Maya Buch

  • Gerd Burmester

  • Beatrix Bartok

  • Alena Pechonkina

  • Ling Han

  • Kahaku Emoto

  • Shungo Kano

  • Thijs Hendrikx

  • Daniel Aletaha

Medical Centers

  • Gilead Sciences, Inc., Foster City, CA

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Montpellier Universitary Hospital, Montpellier, France

  • LUMC, Leiden, Netherlands

  • Charite-University Medicine Berlin, Berlin, Germany

  • University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

  • Gilead Sciences, Inc., Tokyo, Japan

  • Medical University of Vienna, Vienna, Austria

Locations

  • France

  • Japan

  • United Kingdom

  • Germany

  • United States

  • Netherlands

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • C reactive protein

  • Complement Factor B

  • High sensitivity C-reactive protein

Drug/Treatment

  • Methotrexate

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • N/A

Study Id's

  • NCT02889796

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved